Search
forLearn
5 / 801 resultslearn Acetyl Tyrosine
learn myristoyl pentapeptide-17
learn copper tripeptide-1
learn acetyl methionine
Research
5 / 1000+ results research Expression and localization of A rtemis serine 516 phosphorylation in human scalp skin
Artemis phosphorylation at Ser516 may help regulate skin and hair structures.
research How Does pH Fit in with Oscillating Polar Growth?
pH, calcium, and reactive oxygen species regulate plant cell growth, with key roles for NADPH oxidases and plasma membrane H+-ATPases.
research Expression and localization of Sox10 during hair follicle morphogenesis and induced hair cycle
Sox10 is important for hair follicle development and hair growth cycles.
research Unraveling the Link Between Ectodermal Disorders and Primary Immunodeficiencies
Skin abnormalities can indicate immunodeficiency due to shared origins with the immune system.
research REV7: a small but mighty regulator of genome maintenance and cancer development
REV7 is crucial for genome stability and cancer treatment, making it a potential target for therapy.
Community Join
5 / 1000+ resultscommunity Chronostim: What is it and does it work?
Chronostim is a hair treatment with separate day and night formulas containing ingredients like lauric acid, glycyrrhetinic acid, and piroctone olamine. Users discuss its effectiveness for hair loss.
community Protac degradation of the androgen receptor in mice shows good efficacy and no systemic drug could be found
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
community Pyrilutamide ,the molecule’s true nature
Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.
community AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
community Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US_Kintor Pharmaceutical Limited
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.